Tom Fetzer (R) Receiving Treatment for Non-Hodgkin’s Lymphoma

Tom Fetzer, a highly respected North Carolina Republican and former mayor of Raleigh, has revealed that he is fighting a form of non-Hodgkin’s lymphoma. The 55-year-old politician told reporters on Friday that he discovered the disease after getting a check-up to determine why he had been feeling sick and run down for long periods of time.

Recently, the well-known Republican began receiving treatments at the Rex Cancer Center. Despite his health problems, however, he maintains a positive attitude.

"Cancer is a random and unpredictable monster," he said. "My doctors have given me great confidence I will be able to overcome this. They tell me this form of cancer responds well to chemotherapy."

His particular illness stems from cancerous cells developing in white blood cells called lymphocytes – part of the body’s immune system. Then, depending on the seriousness and quickness with which the disease spreads, it offers various levels of treatability.

"The only thing you can really do at a time like this is put your faith in God and leave it up to him and go about your business," Fetzer said.

Fetzer was Raleigh’s mayor from 1993 to 1999. In January, he stepped down from his post as chairman of the N.C. Republican Party in order to form a lobbying and political consulting firm. Much of the credit for the ability of the Republicans to capture the state legislature in last fall’s election has been attributed to his hard work.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap